GlassScriptPhysician profile
Loren S Carroll
NPI 1104168178
$5,400.38
in general payments reported to CMS, 2019-2025
34 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.50 · 2020: $305 · 2021: $352 · 2022: $578 · 2023: $1,173 · 2024: $1,331 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,974 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,974.11 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $864.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $793.81 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Otsuka America Pharmaceutical, INC. | $419.62 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $350.79 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $350.62 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $331.25 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $282.25 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $281.96 | 2021-2025 | Austedo Xr |
| Amgen INC. | $219.21 | 2023-2025 | Repatha, Otezla, Repatha |
| Sumitomo Pharma America, INC. | $178.78 | 2023 | Gemtesa |
| Lundbeck LLC | $176.63 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.30 | 2019-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $106.12 | 2023-2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $93.40 | 2019-2020 | |
| Ardelyx, INC. | $79.07 | 2024-2025 | Ibsrela |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $75.39 | 2020-2021 | |
| Sk Life Science, INC. | $68.83 | 2023 | |
| Nestle Healthcare Nutrition INC. | $66.86 | 2022 | |
| Merck Sharp & Dohme LLC | $57.66 | 2019-2024 | Verquvo, Gardasil, Capvaxive |
| Astellas Pharma US INC | $56.51 | 2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $53.83 | 2022 | |
| Aimmune Therapeutics, INC. | $51.71 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $41.57 | 2024-2025 | Voquezna |
| Eisai INC. | $38.63 | 2020 | |
| Novartis Pharmaceuticals Corporation | $28.62 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $24.21 | 2023 | Ingrezza |
| Neurelis, INC. | $21.80 | 2025 | Valtoco |
| Axsome Therapeutics, INC. | $21.05 | 2025 | Auvelity |
| Mdd US Operations, LLC | $19.60 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.59 | 2021 | |
| Exact Sciences Corporation | $19.34 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $16.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.10 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $14.76 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loren Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.